Novocure Provides Regulatory Update on U.S. FDA Premarket Approval Application for Optune Mya® for Brain Metastases from Non-Small Cell Lung Cancer
Novocure (NVCR) received a Not Approvable Letter from the FDA for its Optune Mya® application for treating brain metastases from non-small cell lung cancer. The FDA cited uncertainty about clinical benefits, not safety concerns. Novocure plans to discuss options with the FDA. The company's products are approved in certain countries for various cancers. NVCR stock may be affected by regulatory outcomes.
How this was made

The 30-second read
Why it matters
The FDA’s Not Approvable Letter indicates the application was not approved due to uncertainty about the degree of clinical benefit, increasing the probability of delays and potential additional clinical evidence requirements.
Market read
A PMA Not Approvable Letter is a direct regulatory de-risking event that can materially change perceived approval odds and timelines.
What to watch
The letter’s rationale centers on uncertainty of clinical benefit, so the market may overreact if Novocure can address endpoints, subgroup analyses, or study design gaps in a targeted resubmission.
Background
Novocure is seeking US approval via PMA for Optune Mya for adult brain metastases from non-small cell lung cancer following stereotactic radiation.
Ticker impact
Novocure received an FDA Not Approvable Letter for its PMA application for Optune Mya in brain metastases from non-small cell lung cancer after stereotactic radiation.
Likely downward pressure as investors reprice the probability/timing of approval and potential need for further studies.
The FDA explicitly denied approval due to uncertainty around clinical benefit, while stating safety was not the issue, which typically shifts focus to efficacy evidence and timelines.
Market effects
Highlights ongoing regulatory scrutiny around clinical benefit uncertainty for device-based oncology therapies and may pressure sentiment across tumor-treating fields and similar modalities.
Limited direct regional spillover beyond US biotech/device regulatory sentiment.
US FDA decision can affect global development and commercialization timelines for the therapy.
Counterpoint
Because the FDA did not raise safety concerns, Novocure may still find a path to approval without new trials, depending on what the agency accepts as sufficient evidence.
Key entities
- companyNovocure
NASDAQ-listed oncology company developing Tumor Treating Fields therapy, including Optune Mya.
- regulatorU.S. Food and Drug Administration (FDA)
Agency that issued the Not Approvable Letter for the PMA application.
- productOptune Mya
Tumor Treating Fields therapy evaluated for brain metastases from non-small cell lung cancer after stereotactic radiation.


